These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 19807332)

  • 1. Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis.
    Doig CJ; Zygun DA; Delaney A; Manns BJ
    Expert Rev Pharmacoecon Outcomes Res; 2004 Feb; 4(1):15-26. PubMed ID: 19807332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
    Kunsdorf-Wnuk A; Marzec-Lewenstein E; Arct-Danielak D; Musioł E; Bohatyrewicz R; Becht R
    Med Sci Monit; 2005 Aug; 11(8):CS49-55. PubMed ID: 16049385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alfa: new preparation. For some cases of severe sepsis?
    Prescrire Int; 2003 Apr; 12(64):55-7. PubMed ID: 12674116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa Eli Lilly.
    de Jonge E
    IDrugs; 2002 Apr; 5(4):363-8. PubMed ID: 15565519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.
    Costa V; Brophy JM
    BMC Anesthesiol; 2007 Jun; 7():5. PubMed ID: 17592639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa activated in clinical practice and the current evidences.
    Soares M; Machado FO; Torres VB; Salluh JI; Amaral AC
    Rev Bras Ter Intensiva; 2008 Jun; 20(2):173-7. PubMed ID: 25307006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose, off-label drotrecogin alfa (xigris) in severe sepsis.
    Wang S; Dabovic K; Spector RS
    P T; 2008 Aug; 33(8):469-76. PubMed ID: 19750177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of sepsis.
    Chalupka AN; Talmor D
    Crit Care Clin; 2012 Jan; 28(1):57-76, vi. PubMed ID: 22123099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving concepts in sepsis definitions.
    Vincent JL; Martinez EO; Silva E
    Crit Care Nurs Clin North Am; 2011 Mar; 23(1):29-39. PubMed ID: 21316566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drotrecogin alfa (activated): specific treatment for serious sepsis].
    Miserachs Aranda N; Soy Muner D; Codina Jané C; Ribas Sala J
    Farm Hosp; 2005; 29(1):55-63. PubMed ID: 15773803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic implications of new therapies in sepsis.
    Wood KA; Angus DC
    Pharmacoeconomics; 2004; 22(14):895-906. PubMed ID: 15362927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sepsis: menu of new approaches replaces one therapy for all.
    Larosa SP
    Cleve Clin J Med; 2002 Jan; 69(1):65-73. PubMed ID: 11811722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical care paper review 2012.
    Sohn JW
    Tuberc Respir Dis (Seoul); 2012 Jul; 73(1):1-10. PubMed ID: 23101019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Sepsis Treatment.
    Rice TW; Bernard GR
    Curr Infect Dis Rep; 2004 Oct; 6(5):354-360. PubMed ID: 15461885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated).
    Annane D; Mira JP; Ware LB; Gordon AC; Sevransky J; Stüber F; Heagerty PJ; Wellman HF; Neira M; Mancini ADj; Russell JA
    Ann Intensive Care; 2012 Jun; 2(1):15. PubMed ID: 22694772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa (activated): the first FDA-approved treatment for severe sepsis.
    Hosac AM
    Proc (Bayl Univ Med Cent); 2002 Apr; 15(2):224-7. PubMed ID: 16333441
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of drotrecogin alfa (activated) in a severe acute respiratory syndrome patient with severe sepsis.
    McRitchie D; Farooq W; Fisher HN
    Can J Infect Dis Med Microbiol; 2008 May; 19(3):258-9. PubMed ID: 19412386
    [No Abstract]   [Full Text] [Related]  

  • 19. Animal models of sepsis.
    Fink MP
    Virulence; 2014 Jan; 5(1):143-53. PubMed ID: 24022070
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.